Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas

1 Views
administrator
administrator
08/09/23

Basem William, MD, MRCP, FACP associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive/

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next